Idasanutlin
Tier C — Watch / tradeIdasanutlin
Targets：MDM2
Indications (approved)：Solid tumour, Acute myeloid leukaemia, Polycythaemia vera, Leukaemia, Acute lymphoblastic leukaemia, Neuroblastoma, 横纹肌样瘤, 畸胎瘤
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| IDAS-001 | 161957-59-1 | 1-(3-chloro-2-fluorophenyl)ethan-1-one |
| IDAS-002 | 75279-53-7 | 2-(4-chloro-2-fluorophenyl)acetonitrile |
| IDAS-003 | - | (Z)-2-(4-chloro-2-fluoro-6-methylphenyl)-3-(3-chloro-2-fluorophenyl)acrylonitrile |
| IDAS-004 | 1447813-21-9 | tert-butyl (E)-2-((3,3-dimethylbutylidene)amino)acetate |
| IDAS-005 | - | tert-butyl (2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxylate |
| IDAS-006 | 1229704-06-6 | (2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxylic acid compound with 2,2,2-trifluoroacetaldehyde (1:1) |
| IDAS-007 | 1219089-31-2 | (2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxylic acid |
| IDAS-008 | 41608-64-4 | methyl 4-amino-3-methoxybenzoate |
| IDAS-009 | 1229705-05-8 | methyl 4-((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamido)-3-methoxybenzoate |
| Code | CAS No. | Intermediate |
|---|---|---|
| IDAS-003 | - | (Z)-2-(4-chloro-2-fluoro-6-methylphenyl)-3-(3-chloro-2-fluorophenyl)acrylonitrile |
| IDAS-010 | 2486-69-3 | 4-amino-3-methoxybenzoic acid |
| IDAS-011 | 73368-41-9 | ethyl 4-amino-3-methoxybenzoate |
| IDAS-012 | 79-04-9Available | 2-chloroacetyl chloride |
| IDAS-013 | 1622908-61-5 | ethyl 4-(2-aminoacetamido)-3-methoxybenzoate hydrochloride |
| IDAS-014 | 1622908-61-5 | ethyl 4-(2-aminoacetamido)-3-methoxybenzoate hydrochloride |
| IDAS-015 | 2987-16-8 | 3,3-dimethylbutanal |
| IDAS-016 | 2034194-92-6 | ethyl (E)-4-(2-((3,3-dimethylbutylidene)amino)acetamido)-3-methoxybenzoate |
| IDAS-017 | 2034194-95-9 | ethyl 4-((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamido)-3-methoxybenzoate |
Frequently asked questions
What are the approved indications of Idasanutlin?
Approved indications include: Solid tumour, Acute myeloid leukaemia, Polycythaemia vera, Leukaemia, Acute lymphoblastic leukaemia, Neuroblastoma, 横纹肌样瘤, 畸胎瘤.
When does the Idasanutlin patent expire?
No public expiry year is available for Idasanutlin yet; this page updates once verified.
How many synthesis routes are recorded for Idasanutlin?
2 synthesis routes are recorded; the shortest is 6 steps with 2.96 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Idasanutlin intermediates?
1 intermediate CAS of Idasanutlin are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Idasanutlin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-10